我們已在上線！進一步了解

MBX Biosciences

MBX

市值 US$23.9億

49.61 USD

-1.10

2.17%

收盤時已更新 10月16日下午4:00 EDT

1天

-2.17%

5天

-6.82%

1個月

-19.43%

3個月

-14.93%

6個月

49.34%

今年迄今

62.39%

1年

260.28%

5年

109.77%

10年

109.77%

關於： MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.

員工： 63

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 16.7%

中性 83.3%

負面 0%

MBX Biosciences to Participate in Upcoming November Investor Conferences

CARMEL, Ind. and BURLINGTON, Mass.

MBX Biosciences to Participate in Upcoming November Investor Conferences

MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade)

MBX Biosciences, Inc. is upgraded to Buy, driven by strong canvuparatide Phase 2 data and a clear path to Phase 3 success in hypoparathyroidism. Canvuparatide's once-weekly dosing and robust efficacy position MBX to challenge Yorvipath's standard-of-care status and potentially capture blockbuster revenues. MBX's early-stage obesity pipeline leverages monthly dosing and prodrug technology, targeting a massive market despite intense competition and development risk.

MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade)

MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

MBX Biosciences to Participate in Upcoming Investor Conferences

CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor conferences:

MBX Biosciences to Participate in Upcoming Investor Conferences

MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer

CARMEL, Ind. and BURLINGTON, Mass.

MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer

MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit

MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth

CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its Board of Directors has appointed Steve Hoerter, current Executive Chairman of the Board, as its new Chairman and Chief Executive Officer. Mr. Hoerter succeeds Kent Hawryluk, who will step down as President, Chief Executive Officer and a member of the Board of Directors. In addition, the Board has appointed John Smither, current Interim Chief Financial Officer, as the Company's new Chief Financial Officer. All leadership changes are effective immediately.

MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth

MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)

I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical profile and differentiated dosing convenience. MBXX's Precision Endocrine Peptide platform enables longer-acting, less frequent dosing, addressing key safety and compliance issues in hypoparathyroidism and obesity. Canvuparatide's Phase 2 data show strong efficacy and patient benefit, but Phase 3 must address PK variability and long-term calcium control risks.

MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript

MBX Biosciences Highlights Sustained Calcium Control In Rare Disease

MBX Biosciences Inc. (NASDAQ:MBX) on Thursday reported full results from its 12-week Avail Phase 2 trial and new one-year data from an ongoing open-label extension study of once-weekly canvuparatide in adults with chronic hypoparathyroidism.

MBX Biosciences Highlights Sustained Calcium Control In Rare Disease

查看新聞排名

價格圖表採用Lightweight Charts™實作